Bispecific Anti-CD19, Anti-CD20 CAR T Cells therapy (University Hospital Basel)

N/A

Report date: 2025/09/11 20:00:08

Base Information

Drug NameBispecific Anti-CD19, Anti-CD20 CAR T Cells therapy (University Hospital Basel)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsB-lymphocyte antigen CD20 modulators

TargetsB-lymphocyte antigen CD19B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Hospital Basel

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Hospital Basel

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellLeukemia, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A